Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - CorMedix reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
CorMedix announced earnings per share of $-0.170 on revenue of $6.81M. Analysts polled by Investing.com EPS of $-0.240 on revenue of $0.
CorMedix 's are down 24% and is trading at $3.140 , still down 64.74% from its 52 week high of $8.02 set on Monday, August 8, 2022.
CorMedix shares gained 10.95% to trade at $3.140 in pre-market trade the report.
CorMedix follows other major Healthcare sector earnings this month
CorMedix's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar